Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis

English version České info

c-Myc (hereafter called Myc) belongs to a family of transcription factors that regulates cell growth, cell proliferation, and differentiation. Myc initiates the transcription of a large cast of genes involved in cell growth by stimulating metabolism and protein synthesis. Some of these, like those involved in glycolysis, may be part of the Warburg effect, which is defined as increased glucose uptake and lactate production in the presence of adequate oxygen supply. In this study, we have taken a mouse-genetics approach to challenge the role of select Myc-regulated metabolic enzymes in tumorigenesis in vivo. By breeding λ-Myc transgenic mice, Apc^Min mice, and p53 knockout mice with mouse models carrying inactivating alleles of Lactate dehydrogenase A (Ldha), 3-Phosphoglycerate dehydrogenase (Phgdh) and Serine hydroxymethyltransferase 1 (Shmt1), we obtained offspring that were monitored for tumor development. Very surprisingly, we found that these genes are dispensable for tumorigenesis in these genetic settings. However, experiments in fibroblasts and colon carcinoma cells expressing oncogenic Ras show that these cells are sensitive to Ldha knockdown. Our genetic models reveal cell context dependency and a remarkable ability of tumor cells to adapt to alterations in critical metabolic pathways. Thus, to achieve clinical success, it will be of importance to correctly stratify patients and to find synthetic lethal combinations of inhibitors targeting metabolic enzymes.

Vyšlo v časopise: Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis. PLoS Genet 8(3): e32767. doi:10.1371/journal.pgen.1002573
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002573

Souhrn

Zdroje

1. EilersMEisenmanRN 2008 Myc's broad reach. Genes Dev 22 2755 2766

2. WagnerAJMeyersCLaiminsLAHayN 1993 c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ 4 879 883

3. Bello-FernandezCPackhamGClevelandJL 1993 The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 90 7804 7808

4. ShimHDoldeCLewisBCWuCSDangG 1997 c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94 6658 6663

5. MiltenbergerRJSukowKAFarnhamPJ 1995 An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 15 2527 2535

6. DangCVLeAGaoP 2009 MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15 6479 6483

7. PatelJHLobodaAPShoweMKShoweLCMcMahonSB 2004 Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 4 562 568

8. RounbehlerRJLiWHallMAYangCFallahiM 2009 Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69 547 553

9. HogartyMDNorrisMDDavisKLiuXEvageliouNF 2008 ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68 9735 9745

10. NilssonJAKellerUBaudinoTAYangCNortonS 2005 Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7 433 444

11. LiMRenSTilliMTFlawsJALubetR 2003 Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity. Oncogene 22 2568 2572

12. GuptaSAhmadNMarengoSRMacLennanGTGreenbergNM 2000 Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60 5125 5133

13. JacobyRFColeCETutschKNewtonMAKelloffG 2000 Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60 1864 1870

14. MitsunagaSClapperMLitwinSWattsPBauerB 1997 Chemopreventive effect of difluoromethylornithine (DFMO) on mouse skin squamous cell carcinomas induced by benzo(a)pyrene. J Cell Biochem Suppl 28–29 81 89

15. MeyskensFLJrMcLarenCEPelotDFujikawa-BrooksSCarpenterPM 2008 Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 1 32 38

16. WangJBEricksonJWFujiRRamachandranSGaoP 2010 Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18 207 219

17. QingGSkuliNMayesPAPawelBMartinezD 2010 Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res 70 10351 10361

18. LeACooperCRGouwAMDinavahiRMaitraA 2010 Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107 2037 2042

19. DavidCJChenMAssanahMCanollPManleyJL 2010 HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463 364 368

20. XieHValeraVAMerinoMJAmatoAMSignorettiS 2009 LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8 626 635

21. GaoPTchernyshyovIChangTCLeeYSKitaK 2009 c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature

22. ChristofkHRVander HeidenMGHarrisMHRamanathanAGersztenRE 2008 The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 230 233

23. ShimHChunYSLewisBCDangCV 1998 A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci U S A 95 1511 1516

24. KovalchukALQiCFTorreyTATaddesse-HeathLFeigenbaumL 2000 Burkitt lymphoma in the mouse. J Exp Med 192 1183 1190

25. WarburgO 1956 On the origin of cancer cells. Science 123 309 314

26. MacfarlaneAJPerryCAMcEnteeMFLinDMStoverPJ 2011 Shmt1 heterozygosity impairs folate-dependent thymidylate synthesis capacity and modifies risk of apcmin-mediated intestinal cancer risk. Cancer Res 71 2098 2107

27. FukasawaKWienerFVande WoudeGFMaiS 1997 Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15 1295 1302

28. SansomOJMenielVSMuncanVPhesseTJWilkinsJA 2007 Myc deletion rescues Apc deficiency in the small intestine. Nature 446 676 679

29. WangYVan BecelaereKJiangPPrzybranowskiSOmerC 2005 A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7 336 347

30. YoshidaKFuruyaSOsukaSMitomaJShinodaY 2004 Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality. J Biol Chem 279 3573 3577

31. PretschWMerkleSFavorJWernerT 1993 A mutation affecting the lactate dehydrogenase locus Ldh-1 in the mouse. II. Mechanism of the LDH-A deficiency associated with hemolytic anemia. Genetics 135 161 170

32. MurphyDJJunttilaMRPouyetLKarnezisAShchorsK 2008 Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14 447 457

33. ZindyFEischenCMRandleDHKamijoTClevelandJL 1998 Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12 2424 2433

34. EischenCMWeberJDRousselMFSherrCJClevelandJL 1999 Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13 2658 2669

35. SchmittCAMcCurrachMEde StanchinaEWallace-BrodeurRRLoweSW 1999 INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13 2670 2677

36. StrasserAHarrisAWBathMLCoryS 1990 Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348 331 333

37. FantinVRSt-PierreJLederP 2006 Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 425 434

38. HöglundANilssonLMForshellLPMacleanKHNilssonJA 2009 Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 113 4281 4288

39. HanahanDWeinbergRA 2000 The hallmarks of cancer. Cell 100 57 70

40. HsuPPSabatiniDM 2008 Cancer cell metabolism: Warburg and beyond. Cell 134 703 707

41. ReeseDMSlamonDJ 1997 HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15 1 8

42. BaudinoTAMcKayCPendeville-SamainHNilssonJAMacleanKH 2002 c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16 2530 2543

43. DewsMHomayouniAYuDMurphyDSevignaniC 2006 Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38 1060 1065

44. PelengarisSLittlewoodTKhanMEliaGEvanG 1999 Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3 565 577

45. MorrishFNerettiNSedivyJMHockenberyDM 2008 The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7 1054 1066

46. UlrichCM 2005 Nutrigenetics in cancer research–folate metabolism and colorectal cancer. J Nutr 135 2698 2702

47. NikiforovMAChandrianiSO'ConnellBPetrenkoOKotenkoI 2002 A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol Cell Biol 22 5793 5800

48. ReimannMLeeSLoddenkemperCDorrJRTaborV 2010 Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17 262 272

49. RempelREMoriSGasparettoMGlozakMAAndrechekER 2009 A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet 5 e1000640 doi:10.1371/journal.pgen.1000640

50. MacFarlaneAJLiuXPerryCAFlodbyPAllenRH 2008 Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetrahydrofolate but is not essential in mice. J Biol Chem 283 25846 25853

51. LocasaleJWGrassianARMelmanTLyssiotisCAMattainiKR 2011 Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43 869 874

52. PossematoRMarksKMShaulYDPacoldMEKimD 2011 Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476 346 350

53. ThornburgJMNelsonKKClemBFLaneANArumugamS 2008 Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 10 R84

54. KitadaSLeoneMSarethSZhaiDReedJC 2003 Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46 4259 4264

55. KimJWDangCV 2005 Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30 142 150

56. ZhongXHHowardBD 1990 Phosphotyrosine-containing lactate dehydrogenase is restricted to the nuclei of PC12 pheochromocytoma cells. Mol Cell Biol 10 770 776

57. KimJWooAJChuJSnowJWFujiwaraY 2010 A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143 313 324

58. DaiRPYuFXGohSRChngHWTanYL 2008 Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status. J Biol Chem 283 26894 26901

59. ZhengLRoederRGLuoY 2003 S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 114 255 266

60. AchouriYRiderMHSchaftingenEVRobbiM 1997 Cloning, sequencing and expression of rat liver 3-phosphoglycerate dehydrogenase. Biochem J 323 Pt 2 365 370

61. GellerAMKotbMY 1989 A binding assay for serine hydroxymethyltransferase. Anal Biochem 180 120 125